Skip to main content
. 2021 May 17;39(20):2247–2256. doi: 10.1200/JCO.21.00280

FIG 2.

FIG 2.

Receiver operating characteristic curves for (A) baseline and (B) percent of change in SULmax and (C) 15 days after PT initiation (C1D15). AUC, area under the curve; PT, pertuzumab and trastuzumab; SULmax, maximum standardized uptake value corrected for lean body mass.